Fundraising Fox

Interpace Biosciences

OTC: IDXG

Parsippany, US · Delaware corporation · 1 known investors

Healthtech

Founders & leadership

CM
Christopher McCarthyChief Financial Officer
TWThomas W. Burnell
Thomas W. BurnellExecutiveOperating Team Member at 1315 Capital
JE
James EarlyCFO
JE
Jack E StoverPresident and CEO

Board

SJ
Stephen J. SullivanBoard director
VA
Vijay AggarwalBoard director
JK
Joseph KeeganBoard director
FR
Fortunato Ron RoccaBoard director

Investors · 1

1315 CapitalPhiladelphia · $5M – $40M

Reported raises · per SEC filings

Form D private placements

$113.1M disclosed across 5 rounds · 2017–2024

▶$47MraisedOct 2024 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen J. SullivanDirector
  • Vijay AggarwalDirector
  • Joseph KeeganDirector
  • Fortunato Ron RoccaDirector
  • Christopher McCarthyExecutive Officer
  • Thomas W. BurnellExecutive Officer, Director
Offering amount
$47M
Amount sold
$47M
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$47MraisedJan 2020 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Felice Schnoll-SussmanDirector
  • Gregory RichardExecutive Officer
  • Eric LevDirector
  • Laurence R. McCarthyDirector
  • Robert GormanDirector
  • Thomas FreeburgExecutive Officer
  • Fortunato Ron RoccaDirector
  • Jack E. StoverExecutive Officer, Director
  • James EarlyExecutive Officer
  • Joseph KeeganDirector
  • Stephen J. SullivanDirector
  • Edward ChanDirector
Offering amount
$47M
Amount sold
$47M
First sale
Jan 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14MraisedJul 2019 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jack E. StoverExecutive Officer, Director
  • James EarlyExecutive Officer
  • Joseph KeeganDirector
  • Stephen J. SullivanDirector
  • Thomas FreeburgExecutive Officer
  • Felice Schnoll-SussmanDirector
  • Gregory RichardExecutive Officer
  • Eric LevDirector
Offering amount
$27M
Amount sold
$14M
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedOct 2017 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory RichardExecutive Officer
  • Felice Schnoll-SussmanDirector
  • James EarlyExecutive Officer
  • Jack E. StoverExecutive Officer, Director
  • Stephen J. SullivanDirector
  • Joseph KeeganDirector
Offering amount
$5M
Amount sold
$5M
Sales commissions
$225K
Placement agents
Maxim Group LLC
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$111.2KraisedJan 2017 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James EarlyExecutive Officer
  • Jack E StoverExecutive Officer, Director
  • Stephen J SullivanDirector
  • Joseph KeeganDirector
Offering amount
$4.1M
Amount sold
$111.2K
Sales commissions
$329.7K
Proceeds to insiders
$111K
Placement agents
Maxim Group LLC
First sale
Jan 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Interpace Biosciences | Morris Plains other | Altssaltss.com · Jun 2026Interpace Biosciences Raises Full Year 2021 Revenue Guidance OTC Markets:IDXGglobenewswire.com

Frequently asked questions

Who are Interpace Biosciences's investors?
Interpace Biosciences's investors include 1315 Capital.
How much funding has Interpace Biosciences raised?
Interpace Biosciences has disclosed $113.1M raised across 5 rounds.
Where is Interpace Biosciences headquartered?
Interpace Biosciences is headquartered in Parsippany, US.